Analyst Ratings For Ligand Pharmaceuticals (NASDAQ:LGND)
Today, Roth Capital raised its price target on Ligand Pharmaceuticals (NASDAQ:LGND) to $171.00 per share.
Some recent analyst ratings include
- 2/2/2018-HC Wainwright Reiterated Rating of Buy.
- 11/20/2017-Deutsche Bank was Downgraded by analysts at Deutsche Bank from a “Hold ” rating to a ” Sell” rating. They now have a $105.00 price target on the stock.
- 8/9/2017-Stephens Reiterated Rating of Overweight.
- 3/11/2016-Sidoti initiated coverage with a Buy rating.
- On 2/15/2018 John L Higgins, CEO, sold 9,000 with an average share price of $157.03 per share and the total transaction amounting to $1,413,270.00.
- On 1/24/2018 John L Higgins, CEO, sold 22,500 with an average share price of $165.00 per share and the total transaction amounting to $3,712,500.00.
- On 1/19/2018 John L Higgins, CEO, sold 28,099 with an average share price of $153.70 per share and the total transaction amounting to $4,318,816.30.
- On 1/10/2018 John W Kozarich, Director, sold 2,500 with an average share price of $145.00 per share and the total transaction amounting to $362,500.00.
- On 12/20/2017 Stephen L Sabba, Director, sold 925 with an average share price of $137.25 per share and the total transaction amounting to $126,956.25.
- On 11/17/2017 Matthew E Korenberg, VP, sold 6,559 with an average share price of $142.63 per share and the total transaction amounting to $935,510.17.
- On 11/16/2017 John L Higgins, CEO, sold 5,269 with an average share price of $142.53 per share and the total transaction amounting to $750,990.57.
Recent Trading Activity for Ligand Pharmaceuticals (NASDAQ:LGND)
Shares of Ligand Pharmaceuticals closed the previous trading session at 154.05 up +0.24 0.16% with shares trading hands.